Increased levels of interferon-γ primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection

Immunology

Volumn 121, Issue 4, 2007, Pages 508-517

  Morais Da Fonseca, Denise ^a   Lopes Silva, Célio ^a   Oliveira E Paula, Marina ^a   Garcia Soares, Edson ^a   Marchal, Gilles ^b   Horn, Cynthia ^c   Deperon Bonato, Vânia Luiza ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUT PASTEUR   (France)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Adjuvant; CpG oligodeoxynucleotides; Culture filtrate proteins; Tuberculosis; Vaccine

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CULTURE FILTRATE PROTEIN; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 5; MYCOBACTERIUM ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HISTOLOGY; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; LUNG; LUNG INJURY; LUNG PARENCHYMA; LUNG TUBERCULOSIS; LYMPHOCYTE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NECROSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL PROTEINS; FEMALE; FREUND'S ADJUVANT; IMMUNIZATION; INTERFERON TYPE II; LUNG; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; TH1 CELLS; TH2 CELLS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447109698     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02597.x     Document Type: Article

References (52)

1. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. In : Bloom, BR, ed. Tuberculosis. Pathogenesis, Protection, and Control. Washington, DC : ASM Press, 1994 : 531 57.
2. Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005 3 : 656 62.
3. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000 97 : 13853 9.
4. Grode L, Seiler P, Baumann S et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest 2005 115 : 2472 9.
5. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004 10 : 1240 4.
6. Brandt L, Skeiky YA, Alderson MR et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 2004 72 : 6622 32.
7. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998 11 (393 537 44.
8. Bonato VL, Goncalves ED, Soares EG, Santos Junior RR, Sartori A, Coelho-Castelo AA, Silva CL. Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis. activation of CD8+ cells, interferon-γ recovery and reduction of lung injury. Immunology 2004 113 : 130 8.
9. Lowrie DB, Tascon RE, Bonato VL et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999 400 : 269 71.
10. Skeiky YA, Alderson MR, Ovendale PJ et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004 172 : 7618 28.
11. Olsen AW, van Pinxteren LAH, Okkels LM, Rasmussen PB, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect Immun 2001 69 : 2773 8.
12. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994 62 : 2536 44.
13. Andersen P, Askgaard D, Ljungqvist L, Bennedsen J, Heron I. Proteins released from Mycobacterium tuberculosis during growth. Infect Immun 1991 19 : 1905 10.
14. Andersen P, Askgaard D, Ljungqvist L, Bentzon MW, Heron I. T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun 1991 59 : 1558 63.
15. Andersen P, Heron I. Specificity of a protective memory immune response against Mycobacterium tuberculosis. Infect Immun 1993 61 : 844 51.
16. Havlir DV, Wallis RS, Boom WH, Daniel TM, Chervenak K, Ellner JJ. Human immune responses to Mycobacterium tuberculosis antigens. Infect Immun 1991 59 : 665 70.
17. Roberts AD, Sonnenberg MG, Ordway DJ, Furney SK, Brennan PJ, Belisle JT, Orme IM. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunol 1995 85 : 502 7.
18. Pal PG, Horwitz MA. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in guinea pig model of pulmonary tuberculosis. Infect Immun 1992 60 : 4781 92.
19. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004 72 : 6148 50.
20. Langermans JAM, Doherty TM, Vervenne RAW et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 2005 23 : 2740 50.
21. Sheiky YAW, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006 4 : 469 76.
22. Lindblad EB, Elhay MJ, Silva R, Appelberg R, Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 1997 65 : 623 9.
23. Klinman DM, Currie D, Gursel I, Verthelyi. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004 199 : 201 16.
24. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995 374 : 546 8.
25. Ballas ZD, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996 157 : 1840 7.
26. Klinman DM, Yi A, Beaucage SL, Conover J, Krieg AM. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNγ. Proc Natl Acad Sci USA 1996 93 : 2879 83.
27. Freidag BL, Melton GB, Collins F, Klinman DM, Cheever A, Stobie L, Suen W, Seder RA. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect Immun 2000 68 : 2948 53.
28. Juffermans NP, Leemand JC, Florquin S, Verbon A, Kolk AH, Speelman P, van Deventer SJH, van der Poll T. CpG Oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect Immun 2002 70 : 147 52.
29. Wongratanacheewin S, Kespichayawattana W, Intachote P, Pichyangkul S, Sermswan RW, Krieg AM, Sirisinha S. Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect Immun 2004 72 (8 4494 502.
30. Kumar S, Jones TR, Oakley MS et al. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun 2004 72 : 949 57.
31. Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J, Walravens K, Letesson JJ. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun 2001 69 : 4816 22.
32. Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Hoffman SL. Interleukin-12 and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun 2001 69 : 1643 9.
33. Bonato VL, Medeiros AI, Lima VM, Dias AR, Faccioliti LH, Silva CL. Downmodulation of CD18 and CD86 on macrophages and VLA-4 on lymphocytes in experimental tuberculosis. Scand J Immunol 2001 54 : 564 73.
34. McDonough KA, Kress Y. Cytotoxicity for lung epithelial cells is a virulence associated phenotype of Mycobacterium tuberculosis. Infect Immun 1995 63 : 4802 11.
35. Sable SB, Verma I, Khuller GK. Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis. Vaccine 2005 23 : 4175 84.
36. Hubbard RD, Flory CM, Collins A. Immunization of mice with mycobacterial culture filtrate proteins. Clin Exp Immunol 1992 87 : 94 8.
37. Hogarth PJ, Jahans KJ, Hecker R, Hewinson RG, Chambers MA. Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs. Vaccine 2003 21 : 977 82.
38. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005 11 (4 Suppl. S63 8.
39. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004 82 : 488 96.
40. Degen WG, Jansen T, Schijns VE. Vaccine adjuvant technology: from mechanistic concepts to practical applications. Expert Rev Vaccines 2003 2 : 327 35.
41. Rao V. Increased expression of Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the protective efficacy of BCG by polarizing host immune responses to the Th2 subtype. Scand J Immunol 2005 61 : 410 7.
42. Hovav AH, Mullerad J, Davidovitch L, Fishman Y, Bigi F, Cataldi A, Bercovier H. The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection. Infect Immun 2003 71 : 3146 54.
43. Majlessi L, Simsova M, Jarvis Z et al. An increase in antimycobacterial Th1-cell response by prime-boost protocols of immunization does not enhance protection against tuberculosis. Infect Immun 2006 74 : 2128 37.
44. Hsieh MJ, Junqueira-Kipinis AP, Hoeffer A, Turner OC, Orme IA. Incorporation of CpG oligodeoxynucleotide fails to enhance the protective efficacy of a subunit vaccine against Mycobacterium tuberculosis. Vaccine 2004 22 : 655 9.
45. Rook GAW, Hernandez-Pando R, Dheda K, Seah GT. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 2004 25 : 483 8.
46. Rook GAW, Dheda K, Zumla A. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting? Vaccine 2005 23 : 2115 20.
47. Hernandez-Pando R, Rook GAW. The role of TNF-alpha in T cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 1994 70 : 2100 7.
48. Rook GAW, Dheda K, Zumla A. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol 2005 5 : 661 7.
49. Van Crevel R, Karyadi E, Preyers F, Leenders M, Kullberg BJ, Nelwan RH, van der Meer JW. Increased production of interleukin-4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J Infect Dis 2000 181 : 1194 7.
50. Seah GT, Scott GM, Rook GAW. Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J Infect Dis 2000 181 : 385 9.
51. Hernandez-Pando R, Aguilar D, Hernandez MLG, Orozco H, Rook GAW. Pulmonary tuberculosis in BALB/c mice with non-functional IL-4 genes. changes in the regulation of fibrosis. Eur J Immunol 2004 34 : 174 83.
52. Hernandez-Pando R, Pavon L, Arriaga K, Orozco H, Madrid-Marina V, Rook GAW. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect Immun 1997 65 : 3317 27.